Gold Prices Pull Back After Record Highs as January Rally Remains Strong 
Indonesian Stocks Plunge as MSCI Downgrade Risk Sparks Investor Exodus 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand 
Asia Stocks Pause as Tech Earnings, Fed Signals, and Dollar Weakness Drive Markets 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
MAS Holds Monetary Policy Steady as Strong Growth Raises Inflation Risks 
Google Disrupts Major Residential Proxy Network IPIDEA 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
The Maire - EuroChem Case: Three Lessons for Global Business 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
U.S. and El Salvador Sign Landmark Critical Minerals Agreement to Boost Investment and Trade 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Pfizer announced on Wednesday, April 28, that it has acquired Amplyx Pharmaceuticals. The company stated that the purchase would bolster its portfolio as it offers the opportunity to strengthen “Pfizer’s expertise and deep heritage in infectious disease.”
As per Reuters, Amplyx Pharmaceuticals is based in San Diego, and it is developing new treatments against drug-resistant microbes in patients with compromised immune systems.
The anti-fungal drug has been named fosmanogepix, and it is now in the second phase of clinical trials.
Pfizer to continue testing on Amplyx’s experimental drug
The New York-headquartered multinational pharmaceutical company acquired Amplyx while it is in the middle of conducting trials for its anti-fungal drug that is hoped to effectively fight off drug-resistant infections that ravage the immune system of patients. Since this is the case, Pfizer will not abandon but continue the clinical trials of this experimental drug.
If Amplyx's fosmanogepix drug will show good results and eventually be approved, it will become the first type of new antifungal treatment to come in the last 20 years. This is an important drug because it can kill fungi, like bacteria, that have turned resistant to common drugs or medicines.
Why Pfizer is further expanding its infectious disease folio
It was estimated that if this kind of drug will not be developed, drug-resistant superbugs may possibly kill at least 10 million people by 2050. This is why Pfizer has been expanding its portfolio for treatments that can fight these threatening superbugs.
Pfizer noted that hospitalized patients’ immune systems tend to become weaker since the drugs they take do not work, and this has become a problem not just for the ill but for doctors as well. This scenario just showed how much people need effective anti-fungal treatments for such patients.
“The COVID-19 pandemic has been a stark reminder of the devastating impact of infectious diseases, highlighting the continuous need for new anti-infective therapies to treat both emerging and difficult to treat bacterial, viral and fungal infections,” Pfizer Hospital’s global president, Angela Lukin, said in a press release. “We are deeply committed to helping patients suffering from infectious diseases, continuously seeking opportunities to build our portfolio of anti-infective therapies.”
